Rituxan (rituximab) - Roche
Treatment-refractory autoimmune glial fibrillary acidic protein astrocytopathy: Clinical features, predictive models, therapy. (PubMed, Neurobiol Dis) - Oct 15, 2026 - "Treatment refractory disease is marked by severe central and peripheral nervous system injury. Convergent clinical and experimental evidence provides a rationale for B cell targeted therapies." 
Journal • CNS Disorders • Immunology • GFAP • NEFL • PTPRC
http://www.ncbi.nlm.nih.gov/pubmed/42874935
 
Cong Gao; Dayang Hui; Haiyan Yao; Huilu Li; Jie Yang; M M Li Huang; M M Peihao Lin; M M Shiyu He; M M Wendong Lai; Shifeng Zhang; Ting Li; Xiaorong Liu; Yaqing Shu; Youming Long
 
Oct 15, 2026
 
Prev Next